Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

doi:10.3350/cmh.2020.0058

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24910

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24910

Title:	Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
Authors:	Yap, DYH;Liu, KSH;Hsu, YC;Wong, GLH;Tsai, MC;Chen, CH;Hsu, CS;Hui, YT;Li, MKK;Liu, CH;Kan, YM;Yu, ML;Yuen, MF
Keywords:	Glecaprevir and pibrentasvir;Hepatitis C;Renal insufficiency
Date:	2020
Issue Date:	2022-08-09T08:09:59Z (UTC)
Publisher:	KOREAN ASSOC STUDY LIVER
ISSN:	2287-2728
Abstract:	[GRAPHICS] Background/Aims: Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with non-1 genotype (GT) HCV. Methods: We prospectively recruited patients with Child's A cirrhosis and eGFR <30 mL/min/1.73 m(2) in Hong Kong and Taiwan during 2017-2018 to receive GLE/PIB treatment. Results: Twenty-one patients (GT2, n=7; GT3, n= 6; and GT6, n=8) received GLE/PIB for 11.2 +/- 1.8 weeks. All except one were treatment-naive. GLE/PIB was initiated in 16 patients while on dialysis (seven on peritoneal dialysis [PD] and nine on hemodialysis) and in five patients before dialysis. One patient died of PD-related peritonitis during treatment and two were lost to follow up. The SVR12 rate in the remaining 18 patients was 100%. All patients achieved undetectable levels at 4-, 12-, 24- and 48-week after treatment. Patients with deranged alanine aminotransferase showed normalization after 4 weeks and the response was sustained for 48 weeks. No significant adverse event was observed. Conclusions: GLE/PIB treatment was associated with high efficacy and tolerability in HCV-infected patients with severe renal impairment.
URI:	http://dx.doi.org/10.3350/cmh.2020.0058 https://www.webofscience.com/wos/woscc/full-record/WOS:000580510600017 https://ir.csmu.edu.tw:8080/handle/310902500/24910
Relation:	CLINICAL AND MOLECULAR HEPATOLOGY ,2020 ,v26 ,issue 4 ,p554-561
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	173	View/Open

Loading...